Immunity Pharma Ltd. (IPL) develops therapies for neurodegenerative diseases with an initial focus on Amyotrophic lateral sclerosis (ALS). ALS is an urgent unmet medical need as no cure is currently available for this disease. A disease-modifying ALS therapy is certain to have a significant market potential.
IPL’s drugs are selective activators of the Akt pathway, which is down-regulated in ALS and other neurodegenerative disorders. Our drugs mitigate ALS disease progression by stimulating cellular pro-survival processes while simultaneously reducing apoptosis (cell death) and inflammation.
IPL’s lead drug, IPL344, is currently evaluated in an ongoing open-label phase 1/2a clinical trial with ALS patients at Hadassah medical center in Israel. Interim results demonstrate promising efficacy and excellent safety profile. Read about the Promising Interim Results of IPL's Study with IPL344 in ALS.